NRx Pharmaceuticals, Inc.
NRXP
$3.28
$0.072.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 103.97% | -262.91% | -122.62% | 15.56% | -109.56% |
| Total Depreciation and Amortization | 9,900.00% | 2,050.00% | -- | -- | 0.00% |
| Total Amortization of Deferred Charges | -100.00% | -100.00% | -- | -- | -- |
| Total Other Non-Cash Items | -182.68% | 291.27% | 515.13% | 195.61% | 621.43% |
| Change in Net Operating Assets | 1,679.07% | 1,218.60% | -116.93% | -100.00% | -103.55% |
| Cash from Operations | -76.98% | -25.37% | -57.22% | 5.20% | 34.27% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -107.65% | -- | -- | 2,535.67% |
| Total Debt Repaid | 95.92% | 100.00% | -7,300.00% | 85.15% | -196.54% |
| Issuance of Common Stock | -- | 2,736.99% | -100.00% | 27.65% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 208.68% | 143.04% | -- | -- | -- |
| Cash from Financing | 141.42% | 373.52% | -55.75% | 1,820.25% | 269.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 401.97% | 1,796.03% | -555.61% | 225.31% | 95.29% |